These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 19043439)

  • 21. End of the line for cannabinoid receptor 1 as an anti-obesity target? An opinion.
    Bifulco M; Pisanti S
    Nat Rev Drug Discov; 2009 Jul; 8(7):594. PubMed ID: 19568284
    [No Abstract]   [Full Text] [Related]  

  • 22. STRADIVARIUS: a brave trial aimed at clarifying benefits of rimonabant therapy.
    Cardiovasc J Afr; 2008; 19(3):158-9. PubMed ID: 18568179
    [No Abstract]   [Full Text] [Related]  

  • 23. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
    Ducobu J; Sternon J
    J Pharm Belg; 2005; 60(3):89-91. PubMed ID: 16252510
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endocannabinoid signalling as an anti-inflammatory therapeutic target in atherosclerosis: does it work?
    Immenschuh S
    Cardiovasc Res; 2009 Dec; 84(3):341-2. PubMed ID: 19819883
    [No Abstract]   [Full Text] [Related]  

  • 25. Recent advances in CB1 cannabinoid receptor antagonists.
    Lange JH; Kruse CG
    Curr Opin Drug Discov Devel; 2004 Jul; 7(4):498-506. PubMed ID: 15338959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endocannabinoid control of food intake and energy balance.
    Di Marzo V; Matias I
    Nat Neurosci; 2005 May; 8(5):585-9. PubMed ID: 15856067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity.
    Leite CE; Mocelin CA; Petersen GO; Leal MB; Thiesen FV
    Pharmacol Rep; 2009; 61(2):217-24. PubMed ID: 19443932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cannabinoid receptor CB1 antagonists state of the art and challenges.
    Bifulco M; Santoro A; Laezza C; Malfitano AM
    Vitam Horm; 2009; 81():159-89. PubMed ID: 19647112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Endocannabinoid and endocannabinoid receptor antagonists].
    Heinzl S
    Med Monatsschr Pharm; 2005 Feb; 28(2):40-3. PubMed ID: 15727333
    [No Abstract]   [Full Text] [Related]  

  • 30. [Selective cannabinoid receptor antagonists].
    Kreutz S; Korf HW; Schubert-Zsilavecz M
    Pharm Unserer Zeit; 2006; 35(6):512-20. PubMed ID: 17137082
    [No Abstract]   [Full Text] [Related]  

  • 31. Cannabinoid CB1 receptor antagonists in therapeutic and structural perspectives.
    Lange JH; Kruse CG
    Chem Rec; 2008; 8(3):156-68. PubMed ID: 18563799
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel selective antagonist of the cannabinoid CB1 receptor, MJ15, with prominent anti-obesity effect in rodent models.
    Chen W; Tang H; Liu H; Long L; Gong Z; Zheng J; Chi M; Xie Y; Zheng Z; Li S; Wang L
    Eur J Pharmacol; 2010 Jul; 637(1-3):178-85. PubMed ID: 20380831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New diet drug stirs high hopes. But can the pill, rimonabant, liver up to large expectations?
    Heart Advis; 2005 Feb; 8(2):3. PubMed ID: 15806687
    [No Abstract]   [Full Text] [Related]  

  • 34. Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.
    Shearman LP; Stribling DS; Camacho RE; Rosko KM; Wang J; Tong S; Feng Y; Marsh DJ; Yu H; Guan X; Spann SK; Macneil DJ; Fong TM; Metzger JM; Goulet MT; Hagmann WK; Plummer CW; Finke PE; Mills SG; Shah SK; Truong Q; Van der Ploeg LH; Macintyre DE; Strack AM
    Eur J Pharmacol; 2008 Jan; 579(1-3):215-24. PubMed ID: 18021763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Feeding disorders and obesity.
    Cervino C; Vicennati V; Pasquali R; Pagotto U
    Curr Top Behav Neurosci; 2009; 1():373-85. PubMed ID: 21104392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS.
    Kintscher U
    Eur Heart J; 2008 Jul; 29(14):1709-10. PubMed ID: 18556715
    [No Abstract]   [Full Text] [Related]  

  • 37. Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects.
    Bifulco M; Grimaldi C; Gazzerro P; Pisanti S; Santoro A
    Mol Pharmacol; 2007 Jun; 71(6):1445-56. PubMed ID: 17327463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [2008: the end of rimonabant's story].
    Paris M
    Ann Pharm Fr; 2009 May; 67(3):167-8. PubMed ID: 19446664
    [No Abstract]   [Full Text] [Related]  

  • 39. Efficacy and safety of the weight-loss drug rimonabant.
    Blüher M
    Lancet; 2008 Feb; 371(9612):555-6; author reply 556-7. PubMed ID: 18280321
    [No Abstract]   [Full Text] [Related]  

  • 40. Weeding out new drugs.
    Ewan S
    Drug Discov Today; 2005 Oct; 10(20):1336-7. PubMed ID: 16253865
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.